Sucrose Malabsorption Found in 22% of SIBO-Negative Patients

Twenty-Two Percent of SIBO-Negative Patients Have Sucrose Malabsorption

A Beth Israel Deaconess Medical Center study of 140 patients reveals a hidden diagnostic factor. When patients tested negative for Small Intestinal Bacterial Overgrowth (SIBO), clinicians considered the case closed. New evidence suggests they should check for sucrose malabsorption. The 13C-sucrose breath test found this condition in 22% of SIBO-negative patients. Symptom questionnaires could not distinguish between the two conditions. This finding forces a re-evaluation of how we diagnose chronic bloating, pain, and altered bowel habits.

Why Overlap Between IBS and SIBO Creates Diagnostic Challenges

Irritable Bowel Syndrome (IBS) is diagnosed by symptoms—recurrent abdominal pain linked to bowel movements—after excluding other diseases. SIBO is a condition defined by an excessive number of bacteria in the small intestine. The core problem is that they present identically. Patients with either condition report bloating, gas, abdominal discomfort, diarrhea, or constipation. This symptom mirroring means a diagnosis based on feeling alone is unreliable.

The Clinical Conundrum of Identical Symptoms

Doctors face a practical issue. A patient describes classic IBS symptoms: cramping, bloating after meals, and erratic bowel habits. These same symptoms are the textbook definition of a positive SIBO breath test. The Beth Israel team confirmed this by administering three standardized symptom surveys: the Rome IV criteria, the IBS Severity Scoring System (IBS-SSS), and the PAGI-SYM index. Scores for pain, bloating frequency, and overall severity showed no statistical difference between those with sucrose malabsorption and those without. The clinical picture is blurred.

Sucrose Malabsorption Emerges as a Third Actor

The 2026 study introduces a complicating factor. Sucrase-isomaltase is the enzyme that breaks down table sugar in the small intestine. When this enzyme is deficient or dysfunctional, sucrose ferments in the gut, producing gas and drawing in water. The resulting symptoms—bloating, gas, diarrhea—perfectly mimic both IBS and SIBO. Lead author Dr. Ramprasad and colleagues show this is not a rare outlier. It is a condition present in at least one in five patients who otherwise receive a generic functional diagnosis.

New Research Exposes the Limits of Symptom-Based Diagnosis

“Clinical Symptoms Do Not Distinguish Sucrose Malabsorption From SIBO,” the Beth Israel paper concludes. This statement has significant implications for clinical practice and patient outcomes.

Data Shows Symptom Profiles Are Not Diagnostic

The research team compared two clear groups: 24 patients with only sucrose malabsorption and 23 patients with only an abnormal SIBO test. The symptom overlap was extensive. The one statistically significant difference was that the sucrose malabsorption group reported less abdominal pain. This single data point is insufficient for a clinician to separate the conditions at the bedside. Predominant bowel habit, Rome IV diagnosis, bloating frequency, and overall severity scores were indistinguishable.

The Imperative for Objective Testing

This evidence argues against relying on symptom patterns to guide treatment. A patient presumed to have IBS-D (diarrhea-predominant IBS) might be treated with gut-brain neuromodulators or a low-FODMAP diet. If their actual pathology is sucrose malabsorption, a simpler, more specific dietary modification—reducing sucrose—could be more effective and less restrictive. Similarly, treating a sucrose malabsorption patient with SIBO antibiotics like rifaximin would likely fail. The study makes a case for the 13C-sucrose breath test as a necessary tool in the diagnostic workup for functional gut symptoms, especially after a negative SIBO test. For more on this specific diagnostic challenge, see our article SIBO vs Sucrose Malabsorption Symptoms.

Stress, Metabolites, and the Gut-Brain Connection in IBS

While SIBO and sucrose malabsorption represent intraluminal problems, IBS pathophysiology often involves the gut-brain axis. Japanese researchers Ishihara, Kimura, and Hase at Keio University are investigating how stress translates into diarrhea. Their work examines specific bacterial metabolites that may act as signaling molecules, exacerbating intestinal motility and secretion in response to psychological stress. This line of inquiry explains why treatments targeting the microbiome or brain-gut communication can help some IBS patients, even in the absence of SIBO.

Emotional Stress as a Primary Risk Factor

The Yakugaku Zasshi review identifies emotional stress as a principal trigger for IBS symptom onset and flares. This is not anecdotal; it is a consistent finding in epidemiological studies. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system, which directly alter gut motility, secretion, and sensitivity. This creates a self-reinforcing cycle: gut symptoms cause distress, and distress worsens gut symptoms.

When Overlapping Conditions Compound the Problem

A patient might have a genuine, stress-exacerbated IBS diagnosis. Concurrently, they could develop SIBO following food poisoning or acquire sucrose malabsorption. The resulting symptom burden is a combination of multiple mechanisms. Treating only one component—for instance, using cognitive behavioral therapy for stress without addressing a concurrent sucrose malabsorption—may yield partial relief at best. This complexity necessitates a systematic, test-guided approach to isolate each contributing factor.

A Practical Framework for Differential Diagnosis

Given that symptoms cannot reliably separate these conditions, clinicians and patients need a structured diagnostic pathway. This approach moves from broad consideration to specific testing.

Step 1: Comprehensive Symptom and History Review

Start with a detailed history, but with the explicit understanding that it will not provide the answer. Use standardized tools like the Rome IV criteria to confirm the functional nature of the symptoms. Document the symptom response to dietary elements, particularly sugary foods, high-FODMAP items, and fiber. Note any history of acute gastroenteritis, antibiotic use, or prolonged PPI use, which are risk factors for SIBO.

Step 2: First-Line Objective Testing for SIBO

The current standard is a glucose or lactulose breath test measuring hydrogen and methane. A positive test indicates SIBO and can guide targeted antibiotic treatment. However, a negative test is not an endpoint. It is, as the Beth Israel study shows, an indication to look further.

Step 3: Investigating Carbohydrate Malabsorption

Following a negative SIBO test, consider testing for specific carbohydrate malabsorptions. The 13C-sucrose breath test is the validated method for sucrose malabsorption. Lactose intolerance can be assessed via a hydrogen breath test. This step is frequently missed, leaving patients with unexplained symptoms. For a detailed guide on navigating this post-SIBO-test decision point, visit SIBO vs IBS: Sucrose Malabsorption Diagnosis Gap.

Step 4: Consideration of Gut-Brain Therapies

If SIBO and specific carbohydrate malabsorptions are ruled out, or if symptoms persist after their treatment, the primary driver likely involves the gut-brain axis. Here, treatments like gut-directed hypnotherapy, low-dose antidepressants, or time-restricted eating to regulate circadian gut function become central to management.

Actionable Takeaways for Patients and Clinicians

The research mandates a shift in strategy from assumption to investigation.

For Patients Seeking Answers

If you have chronic bloating, gas, and bowel changes diagnosed as IBS, ask about testing. A negative SIBO breath test should prompt a discussion about sucrose malabsorption. Prepare for your appointment by tracking your symptoms in relation to specific foods, particularly those high in table sugar, maple syrup, or certain fruits. Understand that your symptoms are real and have a biological basis, even if they are complex to untangle.

For Clinicians Managing Functional GI Disorders

Incorporate the 13C-sucrose breath test into your diagnostic algorithm for patients with functional GI symptoms, particularly those who are SIBO-negative or who respond poorly to a low-FODMAP diet which still allows sucrose. Recognize that “IBS” is often a final common pathway for multiple distinct pathologies. A layered, sequential treatment approach targeting the specific identified abnormality—be it bacterial overgrowth, enzyme deficiency, or brain-gut dysregulation—is more effective than a one-size-fits-all model. Treatment options for confirmed SIBO are reviewed in Rifaximin Best for IBS-D & SIBO Efficacy Safety Review.

💊 Supplements mentioned in this research

Available on iHerb (ships to 180+ countries):

Soluble Fiber on iHerb ↗

Affiliate disclosure: we may earn a small commission at no extra cost to you.